


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. AM100878-P1)

In re Patent Application of:) Appln. No.: 10/808,964
Xiang-Jin Meng *et al.*) Confirmation No.: 7042
) Customer No.: 000044091
) Group Art Unit: 1648
Filed: 03/25/2004) Examiner: Stacy Brown Chen
)
For: CHIMERIC INFECTIOUS DNA CLONES,)
CHIMERIC PORCINE CIRCOVIRUSES)
AND USES THEREOF) Paper No.: 19

AMENDMENT AFTER FINAL REJECTION PURSUANT TO 37 C.F.R. § 1.116

Dear Sir:

Responsive to the Official action mailed August 2, 2006, please amend the above-referenced application using the below instructions and consider the remarks in a positive light:

REMARKS

Reconsideration of this application, as amended, is respectfully requested.

In accord with 37 C.F.R. § 1.121, the proposed amendment to the claims and a listing of all claims in the application begin on a separate sheet. As required, only the claim number and status indicate any canceled claims. The amendment adds no new matter into the application. For the convenience of the Office staff, the amendment is placed in the below Appendix and incorporated herein by reference thereto.

While Applicants appreciate that they cannot amend the finally rejected claims as a matter of right, they believe that presenting the below amendment may place the application in condition for an immediate allowance. Primarily, the amendment is necessary to omit the specific recitation of the chimeric nucleic acid molecule (PCV1-2 construct) having at least 95% homology to the nucleotide sequence of SEQ ID NO:2. The amendment is also warranted to clarify the claimed subject matter and revise the language of Claim 15(b) for the better readability thereof.

Because the amendment is a direct response to the final Official Action of August 2, 2006 and deals with issues already considered by the Examiner, it requires only a cursory review. The

Page 1 of 7